Michelle Buehrle, RHIA

Michelle Buehrle, RHIA

Location
New York, New York (Greater New York City Area)
Industry
Hospital & Health Care

As a LinkedIn member, you'll join 300 million other professionals who are sharing connections, ideas, and opportunities.

  • See who you and Michelle Buehrle, RHIA know in common
  • Get introduced to Michelle Buehrle, RHIA
  • Contact Michelle Buehrle, RHIA directly

View Michelle's full profile

Michelle Buehrle, RHIA's Overview

Current
Education
Connections

188 connections

Michelle Buehrle, RHIA's Experience

Director of Operations, HIM

The Mount Sinai Hospital

Nonprofit; 10,001+ employees; Hospital & Health Care industry

October 2013Present (1 year 1 month) Greater New York City Area

Michelle Buehrle, RHIA's Publications

  • Validation of an in vitro screen for phospholipidosis using a high-content biology platform

    • Cell Biology & Toxicology
    • January 2006
    Authors: J.K. Morelli, Michelle Buehrle, RHIA, F. Pognan, L.R. Barone, W. Fieles, P.J. Ciaccio

    Several cationic amphiphilic drugs cause local or systemic phospholipidosis (PLD) after chronic exposure in preclinical species. PLD is characterized by the accumulation of drug, phospholipid, and concentric lamellar bodies in cellular lysosomes. We have developed a fluorescence-based in vitro screen that is predictive of PLD using the Cellomics ArrayScan high-content screening platform, which captures and analyzes images from 96-well cell culture microtiter plates using multichannel fluorescence microscopy. I-13.35 adherent mouse spleen macrophage cells were cultured with drug and a fluorescently tagged phospholipid, N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE). Drug concentrations were used in a range from 1 to $100 μmol/L. After 24 h incubations, the cells were fixed with formalin. NBD-PE uptake was quantified in controls and treated cells. Nuclei were identified by Hoechst 33258 staining and dead cells were identified using ethidium homodimer-2 incorporation. Thus, confounding accumulation of NBD-PE due to cytotoxicity that produces false-positive results at high concentrations was eliminated from quantitation by ethidium staining and employing cell gating (dead cell rejection). The assay was found to be both sensitive and selective in that 26 of 28 positive, phospholipidogenic controls and 8 of 8 negative, nonphospholipidogenic controls were correctly called.

Michelle Buehrle, RHIA's Skills & Expertise

  1. EMR
  2. Health Information Management
  3. Hospitals
  4. EHR
  5. Healthcare Information Technology
  6. HIPAA
  7. Medical Records
  8. Informatics
  9. Healthcare Management
  10. Project Management
  11. Ambulatory
  12. Acute Care
  13. Cerner
  14. Healthcare Consulting
  15. Healthcare
  16. Inpatient
  17. Quality Improvement
  18. Data Analysis
  19. ICD-9
  20. Revenue Cycle
  21. Epic Systems
  22. Performance Improvement
  23. MPI

View All (23) Skills View Fewer Skills

Michelle Buehrle, RHIA's Courses

  • Independent Coursework

    • Leadership training: Financial Performance, People Development, Quality & Safety, Service Excellence, and Employee Engagement, 2010
    • HIPAA Compliance, May 2005, September 2008, July 2009, May 2011
    • Data Analytics: Knowledge Management & Business Intelligence Provided by The Shams Group, March 2006

Michelle Buehrle, RHIA's Education

Temple University

20032006

Drexel University

20002002

View Michelle Buehrle, RHIA’s full profile to...

  • See who you and Michelle Buehrle, RHIA know in common
  • Get introduced to Michelle Buehrle, RHIA
  • Contact Michelle Buehrle, RHIA directly

View Michelle's full profile

Viewers of this profile also viewed...